Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Given Consensus Recommendation of “Hold” by Analysts


Share on StockTwits

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) have earned an average recommendation of “Hold” from the twenty-five ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, sixteen have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $49.83.

ICPT has been the subject of several research reports. Bank of America lowered Intercept Pharmaceuticals from a “neutral” rating to an “underperform” rating and cut their price objective for the stock from $40.00 to $27.00 in a research note on Friday, January 15th. Wedbush dropped their price target on Intercept Pharmaceuticals from $106.00 to $88.00 and set an “outperform” rating for the company in a research report on Monday, March 8th. HC Wainwright upgraded Intercept Pharmaceuticals from a “sell” rating to a “neutral” rating and dropped their price target for the company from $25.00 to $21.00 in a research report on Thursday, March 18th. Chardan Capital dropped their price target on Intercept Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, March 1st. Finally, B. Riley dropped their price target on Intercept Pharmaceuticals from $74.00 to $65.00 and set a “buy” rating for the company in a research report on Monday, March 1st.

Shares of ICPT stock traded down $0.83 on Thursday, hitting $19.12. The company had a trading volume of 25,696 shares, compared to its average volume of 1,151,307. The firm has a market cap of $634.06 million, a P/E ratio of -2.04 and a beta of 1.85. The company has a 50-day moving average price of $22.10 and a 200-day moving average price of $28.45. Intercept Pharmaceuticals has a twelve month low of $18.15 and a twelve month high of $95.98.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Thursday, February 25th. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.55) by ($0.03). Intercept Pharmaceuticals had a negative return on equity of 1,973.10% and a negative net margin of 106.64%. The business had revenue of $83.27 million during the quarter, compared to analyst estimates of $84.10 million. As a group, sell-side analysts predict that Intercept Pharmaceuticals will post -8.23 earnings per share for the current fiscal year.

In other news, Director Srinivas Akkaraju bought 147,000 shares of the stock in a transaction on Friday, March 12th. The stock was purchased at an average cost of $21.29 per share, with a total value of $3,129,630.00. Following the purchase, the director now owns 23,121 shares of the company’s stock, valued at $492,246.09. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 23.70% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. First Trust Advisors LP lifted its holdings in shares of Intercept Pharmaceuticals by 29.6% during the 4th quarter. First Trust Advisors LP now owns 1,956,302 shares of the biopharmaceutical company’s stock valued at $48,321,000 after acquiring an additional 447,294 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Intercept Pharmaceuticals by 78.6% during the 4th quarter. Renaissance Technologies LLC now owns 437,000 shares of the biopharmaceutical company’s stock valued at $10,794,000 after acquiring an additional 192,300 shares in the last quarter. Voloridge Investment Management LLC lifted its holdings in shares of Intercept Pharmaceuticals by 17.9% during the 4th quarter. Voloridge Investment Management LLC now owns 371,324 shares of the biopharmaceutical company’s stock valued at $9,172,000 after acquiring an additional 56,485 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Intercept Pharmaceuticals by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 202,701 shares of the biopharmaceutical company’s stock valued at $5,007,000 after acquiring an additional 1,631 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Intercept Pharmaceuticals during the 4th quarter valued at $4,782,000. 85.77% of the stock is owned by institutional investors.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Featured Story: Intrinsic Value

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.